Meeting
2013 ASCO Annual Meeting
Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
Authors
M. Pia Morelli
The University of Texas MD Anderson Cancer Center, Houston, TX
M. Pia Morelli , Michael J. Overman , Arvind Dasari , Syed Mohammad Ali Kazmi , Eduardo Vilar Sanchez , Cathy Eng , Laurel Deaton , Chris R. Garrett , Frank Diehl , Philipp Angenendt , Scott Kopetz , Bryan K. Kee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3512)
DOI
10.1200/jco.2013.31.15_suppl.3512
Abstract #
3512
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
EGFR and KRAS mutations during anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer: Clinically relevant?
First Author: Lucie Karayan-Tapon
Poster
2014 Gastrointestinal Cancers Symposium
Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.
First Author: Gargi Dan Basu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive benefit from EGFR inhibitors (EGFRi).
First Author: Ramya Thota
Poster
2018 Gastrointestinal Cancers Symposium
Molecular rationale for ERK and EGFR inhibition in colorectal cancer.
First Author: Timothy Joseph Yeatman